For estimating the influence of mTOR polymorphisms (rs2295080 and rs11121704) on clinical outcomes in cancer patients, 4 eligible studies included 1594 cancer patients, were identified: 2 were conducted in USA [19], [20] and two were in China [14], [35]. Here, MTOR is linked to cancer.